Vasculitis & polymyalgia rheumatica
Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases
Authors' conclusion
In a population with autoimmune or inflammatory diseases at risk of severe COVID-19 unresponsive to vaccination, pre-exposure prophylaxis withy tixagevimab/cilgavimab was associated with a lower incidence of COVID-19 and no severe infections.
Study context
- Population
- Rheumatology patients with autoimmune or inflammatory diseases at risk of severe COVID-19 and unresponsive to vaccination (anti-SARS-CoV-2 antibodies <260 binding antibody units/ml); median age 62 years (IQR 52–71); chronic arthritis, connective tissue disease, vasculitis; main immunosuppressants RTX, GC and MTXchronic arthritis 53 · connective tissue disease 38 · vasculitis 11 · main immunosuppressants RTX 98 · GC 62 · MTX 48
- Participants
- 115 patients
- Outcome
- Incidence of COVID-19 and its severity
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Patients with COVID-19, 23/115
20%
Average weekly incidence in study patients, per 100 000
588
Average weekly incidence in Île-de-France population, per 100 000 inhabitants
1071
Observational data: associations, not effects.
Further findings
Average weekly COVID-19 incidence, study patients vs Île-de-France population
- Île-de-France inhabitants
- 1071/100 000
- Study patients
- 588/100 000
Infection risk, two-injection vs single-injection regimen
- Two-injection regimen had a lower risk of infection than a single injection
- 16/49 (33%) vs 5/64 (8%), P = 0.0012
Characteristics of COVID-19-positive vs uninfected patients
- No difference in age, comorbidities, underlying rheumatic disease and immunosuppressants
Safety
- Tolerance of injections was excellent
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →